A practical reference on Agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-23. Anything still debated is marked as such rather than presented as settled.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
| Property | Value | Notes |
|---|---|---|
| Primary receptor family | Melanocortin (MC1 to MC5) | Agonist activity reported at several subtypes |
| Signalling pathway | Gs, adenylyl cyclase, cyclic AMP | Canonical melanocortin signalling route |
| Backbone length | Seven amino acids | Classified as a cyclic heptapeptide |
| Ring closure | Lactam bridge | Constrains conformation and resists peptidases |
| Terminal modifications | Acetylated N-terminus, amidated C-terminus | Reduces breakdown by exopeptidases |
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
Since thaumatin crystallizes very quickly and easily in the presence of tartrate ions, thaumatin-tartrate mixtures are frequently used as model systems to study protein crystallization. The solubility of thaumatin, its crystal habit, and mechanism of crystal formation are dependent upon the chirality of precipitant used. When crystallized with L- tartrate, thaumatin forms bipyramidal crystals and displays a solubility that increases with temperature; with D- and meso-tartrate, it forms stubby and prismatic crystals and displays a solubility that decreases with temperature. This suggests control of precipitant chirality may be an important factor in protein crystallization in general.
==== Changes in the Government ==== In the fourth cabinet, of the nineteen appointed ministers, thirteen are re-elected to their positions and six are new ministers, highlighting Heidy Juárez, Silvana Robles, and Cinthya Lindo Espinoza. Following the announcement by Vice President Dina Boluarte that she will not continue as minister, justifying that "the current polarization harms everyone" and preferring to consolidate "the broadest unity of all Peruvians" as vice president, Minister Roberto Sánchez is the longest-serving minister of Pedro Castillo's mandate, since the first cabinet of Guido Bellido. Since November, he has been described by the media as close to the president and is also implicated in the corruption scandals against Pedro Castillo. What is surprising is the appointment of Heidy Juárez as Minister of Women and Vulnerable Populations, she is also a representative and former member of APP, expelled from the group and left for being the author and revealing, according to the APP party, the matter of the audio recordings that caused Lady Camones to be censored from the presidency of Congress by the left and center groups. Following this expulsion, he became a member of the Podemos Perú parliamentary group. However, when she was appointed to the government, she was still a member of the Podemos Perú parliamentary group, but the latter, through the group's president, José Luna Gálvez, expressed its disagreement with this choice, stating that it did not support or was linked to the government.
== Awards and fellowships == 1984 ACS Analytical Division's Chemical Instrumentation Award; 1985 Thomson Medal for International Service to Mass Spectrometry; 1990 and 1995 NSF Special Creativity Award; 1991 Frank H. Field & Joe Franklin Award, (ACS Award for Mass Spectrometry); 1997 Fisher Award (ACS Award for Analytical Chemistry); 2006 Distinguished Contribution in Mass Spectrometry Award; 2008 Robert Boyle Prize for Analytical Science; 2012 F.A. Cotton Medal for Excellence in Chemical Research of the American Chemical Society; 2013 Dreyfus Prize in the Chemical Sciences; 2014 ACS Nobel Laureate Signature Award for Graduate Education in Chemistry, shared with graduate student Livia S. Eberlin; 2015 Member, National Academy of Sciences; 2017 Aston Medal, British Mass Spectrometry Society.
=== Pregnancy and breastfeeding === Although there are no major human studies of prednisolone use in pregnant women, studies in several animals show that it may cause birth defects including increased likelihood of cleft palate. Prednisolone is found in the breast milk of mothers taking prednisolone.
Sources: en.wikipedia.org
The advantages of supercritical fluid extraction (compared with liquid extraction) are that it is relatively rapid because of the low viscosities and high diffusivities associated with supercritical fluids. Alternative solvents to supercritical fluids may be poisonous, flammable or an environmental hazard to a much larger extent than water or carbon dioxide are. The extraction can be selective to some extent by controlling the density of the medium, and the extracted material is easily recovered by simply depressurizing, allowing the supercritical fluid to return to gas phase and evaporate leaving little or no solvent residues. Carbon dioxide is the most common supercritical solvent. It is used on a large scale for the decaffeination of green coffee beans, the extraction of hops for beer production, and the production of essential oils and pharmaceutical products from plants. A few laboratory test methods include the use of supercritical fluid extraction as an extraction method instead of using traditional solvents.
Carbon has the highest melting point of any element, and in carbon arc lamps it had been demonstrated to produce incandescence fairly close to that of sunlight. However, carbon has a tendency to sublimate before reaching its melting point depending on pressure, which led to rapid blackening of vacuumed bulbs. The first commercially successful light bulb filaments were made from carbonized paper or bamboo. Carbon filaments have a negative temperature coefficient of resistance—as they get hotter, their electrical resistance decreases. This made the lamp sensitive to fluctuations in the power supply, since a small increase of voltage would cause the filament to heat up, reducing its resistance and causing it to draw even more power and heat even further. Carbon filaments were "flashed" by heating in a hydrocarbon vapor (usually gasoline), to improve their strength and uniformity. Metallized or "graphitized" filaments were first heated to high temperature to transform them into graphite, which further strengthened and smoothed the filament. These filaments have a positive temperature coefficient, like a metallic conductor, which stabilized the lamps operating properties against minor variations in supply voltage. Metal filaments were tried in 1897 and started to displace carbon starting around 1904. Tungsten has the highest available melting point, but brittleness was an obstacle. By 1910, a process was developed by William D. Coolidge at General Electric for production of a ductile form of tungsten.
Producing better protein: the evolution of T7 bacteriophages on a non-evolving E. coli strain that encoded 3-iodotyrosine on the amber codon, resulted in a population fitter than wild-type thanks to the presence of iodotyrosine in its proteome Probing protein localization and protein-protein interaction in bacteria.
. Subsequently, Derjaguin and his collaborators by applying Bradley's surface force law to an elastic half space, confirmed that as the Tabor parameter increases, the pull-off force falls from the Bradley value
On 23 May 2013, Essendon CEO Ian Robson resigned, agreeing with the Switkowski report's assessment that a lack of proper process had occurred in 2012. In late July, Essendon chairman David Evans resigned due to health concerns, and was replaced by deputy chairman Paul Little, who had served on the board since 2011. At the same time as Essendon was being investigated, the Cronulla-Sutherland Sharks club from the National Rugby League was also under investigation for its 2011 supplements program. Stephen Dank was a common factor, as he had been employed at Cronulla as a sports scientist during that program; he was later banned for life from involvement in rugby league for his role in that program.
Sources: en.wikipedia.org
=== Understanding before science === The value of eating certain foods to maintain health was recognized long before vitamins were identified in modern science. The ancient Egyptians knew that feeding liver to a person may help with night blindness, an illness now known to be caused by a vitamin A deficiency. The advance of ocean voyages during the Age of Discovery resulted in prolonged periods without access to fresh fruits and vegetables, and made illnesses from vitamin deficiency common among ships' crews.
== History == Epidemics of meningococcal A meningitis, which is a bacterial infection of the thin lining surrounding the brain and spinal cord, have swept across 26 countries in sub-Saharan Africa for a century, killing and disabling young people every year. The disease is highly feared on the continent; it can kill or cause severe brain damage in a child within hours. Epidemics usually start at the beginning of the calendar year when dry sands from the Sahara Desert begin blowing southward. The largest meningitis epidemic in African history swept across sub-Saharan Africa from 1996 to 1997, numbering 250,000 new cases and taking 25,000 lives. Three years later, the World Health Organization (WHO) held a technical consultation in Cairo, Egypt with African ministers of health and global health leaders to discuss meningitis and the development of a new vaccine. At that meeting, representatives from eight African countries issued a statement saying that the development of a meningococcal vaccine to prevent epidemics was a high priority for them, and concluded that a conjugate meningococcal vaccine would have the potential to prevent future epidemics. They estimated that the new vaccine could become available in three to seven years for US$0.40 to $1 a dose, providing protection for at least ten years. A year later, in 2001, the Bill & Melinda Gates Foundation provided a ten-year, $70 million grant to establish the Meningitis Vaccine Project, a partnership between PATH and WHO.
or greater and depend on impurity concentration. Near zero carrier density, graphene exhibits positive photoconductivity and negative photoconductivity at high carrier density, governed by the interplay between photoinduced changes of both the Drude weight and the carrier scattering rate. Graphene doped with various gaseous species (both acceptors and donors) can be returned to an undoped state by gentle heating in a vacuum. Even for dopant concentrations in excess of 1012 cm−2, carrier mobility exhibits no observable change. Graphene doped with potassium in ultra-high vacuum at low temperature can reduce mobility 20-fold. The mobility reduction is reversible on heating the graphene to remove the potassium. Due to graphene's two dimensions, charge fractionalization (where the apparent charge of individual pseudoparticles in low-dimensional systems is less than a single quantum) is thought to occur. It may therefore be a suitable material for constructing quantum computers using anyonic circuits.
== External links == Anatomy Atlases – Microscopic Anatomy, plate 07.141 - "Axillary Sweat Gland: Myoepithelium" Histology image: 43_13 at the University of Oklahoma Health Sciences Center - "thick skin" Histology at KUMC glands-glands09 "Simple Tubular Coiled" Costoff, A., Essentials of Human Physiology, archived from the original on 2015-11-20{{citation}}: CS1 maint: bot: original URL status unknown (link)
Sources: en.wikipedia.org
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.
The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.
Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.